nodes	percent_of_prediction	percent_of_DWPC	metapath
Alitretinoin—CYP1A2—Methimazole—Graves' disease	0.25	1	CbGbCtD
Alitretinoin—Glomerulonephritis—Propylthiouracil—Graves' disease	0.0599	0.146	CcSEcCtD
Alitretinoin—Allergic cutaneous angiitis—Propylthiouracil—Graves' disease	0.0344	0.0837	CcSEcCtD
Alitretinoin—Erythema nodosum—Propylthiouracil—Graves' disease	0.0253	0.0616	CcSEcCtD
Alitretinoin—Lung infiltration—Propylthiouracil—Graves' disease	0.0233	0.0568	CcSEcCtD
Alitretinoin—Leukocytoclastic vasculitis—Propylthiouracil—Graves' disease	0.0223	0.0543	CcSEcCtD
Alitretinoin—CRABP1—eye—Graves' disease	0.0213	0.0726	CbGeAlD
Alitretinoin—CRABP1—connective tissue—Graves' disease	0.0206	0.0699	CbGeAlD
Alitretinoin—CRABP2—eye—Graves' disease	0.0193	0.0656	CbGeAlD
Alitretinoin—CRABP2—connective tissue—Graves' disease	0.0186	0.0632	CbGeAlD
Alitretinoin—RXRG—eye—Graves' disease	0.0169	0.0574	CbGeAlD
Alitretinoin—CRABP1—pituitary gland—Graves' disease	0.0158	0.0539	CbGeAlD
Alitretinoin—RXRB—Vitamin D Metabolism—GC—Graves' disease	0.0158	0.348	CbGpPWpGaD
Alitretinoin—CRABP2—pituitary gland—Graves' disease	0.0143	0.0487	CbGeAlD
Alitretinoin—CRABP2—adipose tissue—Graves' disease	0.0143	0.0485	CbGeAlD
Alitretinoin—RARG—eye—Graves' disease	0.0141	0.0479	CbGeAlD
Alitretinoin—Skin ulcer—Propylthiouracil—Graves' disease	0.014	0.0342	CcSEcCtD
Alitretinoin—CRABP1—thyroid gland—Graves' disease	0.0137	0.0464	CbGeAlD
Alitretinoin—RXRG—pituitary gland—Graves' disease	0.0125	0.0426	CbGeAlD
Alitretinoin—RXRG—adipose tissue—Graves' disease	0.0125	0.0424	CbGeAlD
Alitretinoin—CRABP2—thyroid gland—Graves' disease	0.0124	0.042	CbGeAlD
Alitretinoin—Vasculitis—Propylthiouracil—Graves' disease	0.0112	0.0273	CcSEcCtD
Alitretinoin—RARB—thyroid gland—Graves' disease	0.011	0.0375	CbGeAlD
Alitretinoin—Lymphadenopathy—Methimazole—Graves' disease	0.0109	0.0266	CcSEcCtD
Alitretinoin—RXRG—thyroid gland—Graves' disease	0.0108	0.0367	CbGeAlD
Alitretinoin—RARG—adipose tissue—Graves' disease	0.0104	0.0354	CbGeAlD
Alitretinoin—RXRB—thyroid gland—Graves' disease	0.0102	0.0345	CbGeAlD
Alitretinoin—RARA—pituitary gland—Graves' disease	0.00983	0.0334	CbGeAlD
Alitretinoin—RARA—adipose tissue—Graves' disease	0.00979	0.0333	CbGeAlD
Alitretinoin—Lymphadenopathy—Propylthiouracil—Graves' disease	0.0093	0.0226	CcSEcCtD
Alitretinoin—RARG—thyroid gland—Graves' disease	0.00901	0.0306	CbGeAlD
Alitretinoin—Renal failure acute—Propylthiouracil—Graves' disease	0.0086	0.0209	CcSEcCtD
Alitretinoin—RARA—thyroid gland—Graves' disease	0.00847	0.0288	CbGeAlD
Alitretinoin—Dermatitis exfoliative—Propylthiouracil—Graves' disease	0.00841	0.0205	CcSEcCtD
Alitretinoin—RXRA—Vitamin D Metabolism—GC—Graves' disease	0.00824	0.181	CbGpPWpGaD
Alitretinoin—Drowsiness—Methimazole—Graves' disease	0.00719	0.0175	CcSEcCtD
Alitretinoin—Neuropathy peripheral—Methimazole—Graves' disease	0.00705	0.0172	CcSEcCtD
Alitretinoin—Agranulocytosis—Methimazole—Graves' disease	0.00671	0.0163	CcSEcCtD
Alitretinoin—Hepatitis—Methimazole—Graves' disease	0.00646	0.0157	CcSEcCtD
Alitretinoin—Drowsiness—Propylthiouracil—Graves' disease	0.00612	0.0149	CcSEcCtD
Alitretinoin—Neuropathy peripheral—Propylthiouracil—Graves' disease	0.00599	0.0146	CcSEcCtD
Alitretinoin—Agranulocytosis—Propylthiouracil—Graves' disease	0.00571	0.0139	CcSEcCtD
Alitretinoin—Alopecia—Methimazole—Graves' disease	0.00571	0.0139	CcSEcCtD
Alitretinoin—Haemoglobin—Propylthiouracil—Graves' disease	0.00552	0.0134	CcSEcCtD
Alitretinoin—Haemorrhage—Propylthiouracil—Graves' disease	0.00549	0.0134	CcSEcCtD
Alitretinoin—Hepatitis—Propylthiouracil—Graves' disease	0.00549	0.0134	CcSEcCtD
Alitretinoin—Alopecia—Propylthiouracil—Graves' disease	0.00485	0.0118	CcSEcCtD
Alitretinoin—Arthralgia—Methimazole—Graves' disease	0.00478	0.0117	CcSEcCtD
Alitretinoin—Myalgia—Methimazole—Graves' disease	0.00478	0.0117	CcSEcCtD
Alitretinoin—Oedema—Methimazole—Graves' disease	0.00459	0.0112	CcSEcCtD
Alitretinoin—Thrombocytopenia—Methimazole—Graves' disease	0.00449	0.0109	CcSEcCtD
Alitretinoin—Musculoskeletal discomfort—Methimazole—Graves' disease	0.00418	0.0102	CcSEcCtD
Alitretinoin—Paraesthesia—Methimazole—Graves' disease	0.00412	0.01	CcSEcCtD
Alitretinoin—Somnolence—Methimazole—Graves' disease	0.00408	0.00993	CcSEcCtD
Alitretinoin—Arthralgia—Propylthiouracil—Graves' disease	0.00407	0.00991	CcSEcCtD
Alitretinoin—Myalgia—Propylthiouracil—Graves' disease	0.00407	0.00991	CcSEcCtD
Alitretinoin—Dyspepsia—Methimazole—Graves' disease	0.00404	0.00983	CcSEcCtD
Alitretinoin—Oedema—Propylthiouracil—Graves' disease	0.0039	0.0095	CcSEcCtD
Alitretinoin—Thrombocytopenia—Propylthiouracil—Graves' disease	0.00382	0.0093	CcSEcCtD
Alitretinoin—Urticaria—Methimazole—Graves' disease	0.00364	0.00887	CcSEcCtD
Alitretinoin—Body temperature increased—Methimazole—Graves' disease	0.00363	0.00883	CcSEcCtD
Alitretinoin—Musculoskeletal discomfort—Propylthiouracil—Graves' disease	0.00355	0.00865	CcSEcCtD
Alitretinoin—Paraesthesia—Propylthiouracil—Graves' disease	0.0035	0.00853	CcSEcCtD
Alitretinoin—Somnolence—Propylthiouracil—Graves' disease	0.00347	0.00844	CcSEcCtD
Alitretinoin—Dyspepsia—Propylthiouracil—Graves' disease	0.00343	0.00836	CcSEcCtD
Alitretinoin—Pruritus—Methimazole—Graves' disease	0.00325	0.0079	CcSEcCtD
Alitretinoin—CYP1A2—thyroid gland—Graves' disease	0.00314	0.0107	CbGeAlD
Alitretinoin—Urticaria—Propylthiouracil—Graves' disease	0.0031	0.00755	CcSEcCtD
Alitretinoin—Body temperature increased—Propylthiouracil—Graves' disease	0.00308	0.00751	CcSEcCtD
Alitretinoin—Vomiting—Methimazole—Graves' disease	0.00292	0.0071	CcSEcCtD
Alitretinoin—Rash—Methimazole—Graves' disease	0.00289	0.00704	CcSEcCtD
Alitretinoin—Dermatitis—Methimazole—Graves' disease	0.00289	0.00704	CcSEcCtD
Alitretinoin—Headache—Methimazole—Graves' disease	0.00287	0.007	CcSEcCtD
Alitretinoin—Pruritus—Propylthiouracil—Graves' disease	0.00276	0.00672	CcSEcCtD
Alitretinoin—Nausea—Methimazole—Graves' disease	0.00272	0.00663	CcSEcCtD
Alitretinoin—Vomiting—Propylthiouracil—Graves' disease	0.00248	0.00604	CcSEcCtD
Alitretinoin—Rash—Propylthiouracil—Graves' disease	0.00246	0.00599	CcSEcCtD
Alitretinoin—Dermatitis—Propylthiouracil—Graves' disease	0.00246	0.00598	CcSEcCtD
Alitretinoin—Headache—Propylthiouracil—Graves' disease	0.00244	0.00595	CcSEcCtD
Alitretinoin—Nausea—Propylthiouracil—Graves' disease	0.00232	0.00564	CcSEcCtD
Alitretinoin—ABCB1—pituitary gland—Graves' disease	0.00187	0.00635	CbGeAlD
Alitretinoin—ABCB1—adipose tissue—Graves' disease	0.00186	0.00632	CbGeAlD
Alitretinoin—ABCB1—thyroid gland—Graves' disease	0.00161	0.00547	CbGeAlD
Alitretinoin—RXRA—Orphan transporters—GABRA3—Graves' disease	0.00118	0.0259	CbGpPWpGaD
Alitretinoin—RARG—RXR and RAR heterodimerization with other nuclear receptor—TNF—Graves' disease	0.00113	0.025	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.00107	0.0236	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.00107	0.0236	CbGpPWpGaD
Alitretinoin—RXRG—RXR and RAR heterodimerization with other nuclear receptor—TNF—Graves' disease	0.00104	0.0228	CbGpPWpGaD
Alitretinoin—RARB—RXR and RAR heterodimerization with other nuclear receptor—TNF—Graves' disease	0.00102	0.0224	CbGpPWpGaD
Alitretinoin—RXRB—RXR and RAR heterodimerization with other nuclear receptor—TNF—Graves' disease	0.000975	0.0215	CbGpPWpGaD
Alitretinoin—RARA—RXR and RAR heterodimerization with other nuclear receptor—TNF—Graves' disease	0.000975	0.0215	CbGpPWpGaD
Alitretinoin—RXRG—Adipogenesis—FAS—Graves' disease	0.000674	0.0148	CbGpPWpGaD
Alitretinoin—RARA—Adipogenesis—FAS—Graves' disease	0.000634	0.014	CbGpPWpGaD
Alitretinoin—RXRA—Transcription factor regulation in adipogenesis—TNF—Graves' disease	0.000581	0.0128	CbGpPWpGaD
Alitretinoin—RXRA—RXR and RAR heterodimerization with other nuclear receptor—TNF—Graves' disease	0.000508	0.0112	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	0.000504	0.0111	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	0.000486	0.0107	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	0.000483	0.0106	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—GC—Graves' disease	0.000478	0.0105	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—GC—Graves' disease	0.000478	0.0105	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	0.000466	0.0103	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—B3GNT2—Graves' disease	0.000362	0.00798	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—B3GNT2—Graves' disease	0.000362	0.00798	CbGpPWpGaD
Alitretinoin—RXRA—Adipogenesis—FAS—Graves' disease	0.00033	0.00727	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.000325	0.00715	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—HLA-E—Graves' disease	0.000293	0.00644	CbGpPWpGaD
Alitretinoin—RXRA—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.000287	0.00632	CbGpPWpGaD
Alitretinoin—RXRG—Adipogenesis—TNF—Graves' disease	0.000286	0.0063	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—CD40—Graves' disease	0.000286	0.0063	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—CTLA4—Graves' disease	0.000282	0.00621	CbGpPWpGaD
Alitretinoin—RARA—Adipogenesis—TNF—Graves' disease	0.000269	0.00592	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	0.000252	0.00554	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	0.000243	0.00534	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—HLA-DQB1—Graves' disease	0.000232	0.00511	CbGpPWpGaD
Alitretinoin—RXRA—Transcriptional regulation of white adipocyte differentiation—TNF—Graves' disease	0.000213	0.00469	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—HLA-B—Graves' disease	0.000209	0.00459	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	0.000206	0.00454	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—FASLG—Graves' disease	0.000204	0.00449	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	0.000198	0.00435	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—FAS—Graves' disease	0.000197	0.00433	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—IL2RA—Graves' disease	0.000195	0.0043	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—HLA-A—Graves' disease	0.000193	0.00425	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—HLA-DRB1—Graves' disease	0.000177	0.00389	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—Graves' disease	0.000159	0.00349	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—GC—Graves' disease	0.000145	0.00319	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—Graves' disease	0.000142	0.00312	CbGpPWpGaD
Alitretinoin—RXRA—Adipogenesis—TNF—Graves' disease	0.00014	0.00309	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—IFNG—Graves' disease	0.000129	0.00284	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—IL1B—Graves' disease	0.000115	0.00253	CbGpPWpGaD
Alitretinoin—ABCB1—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.000115	0.00253	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—B3GNT2—Graves' disease	0.00011	0.00241	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.000104	0.00228	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	0.000103	0.00227	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—Graves' disease	0.000103	0.00226	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—TNF—Graves' disease	0.000103	0.00226	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	0.000101	0.00221	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	9.7e-05	0.00214	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—TNF—Graves' disease	8.35e-05	0.00184	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—GC—Graves' disease	5.78e-05	0.00127	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—TNF—Graves' disease	4.82e-05	0.00106	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—GC—Graves' disease	4.62e-05	0.00102	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—B3GNT2—Graves' disease	4.38e-05	0.000965	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	4.12e-05	0.000907	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—B3GNT2—Graves' disease	3.5e-05	0.00077	CbGpPWpGaD
